

## DAFTAR PUSTAKA

- A, El-Shakmak., A, Sz'ab'ó., M.L, Gross., *et al.* (2003).ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.*Diabetologia*, 46 (6).856–868.
- Abbate, M., Batani, C.,Benigni, A.,Buelli, S., Corna, D.,Donadelli, R., *et al.*(2003).Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kappaB- and p38 mitogen-activated protein kinasedependent pathways.*J Am Soc Nephro*, 14. 2436–2446.
- Abbott, R.D., Curb, J.D., Rodriguez, B.L., *et al.* (2003). Age-related changes in risk factor effects on the incidence of thromboembolic and hemorrhagic stroke. *J Clin Epidemiol*, 56, 479–486.
- Allen, M.D., Alpers, C.E., Chait, A.,McDonald, T.O.,O'Brien, K.D. (1996).Neovascular expression ofE-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 inhuman atherosclerosis and their relation to intimal leukocyte content.*Circulation*, 93, 672–682.
- Anders, H. J., & Ryu, M. (2011). Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. *Kidney Int*, 80, 915–925.
- Audette, J.L.,Carlson, EC., Veitenheimer, N.J., *et al.*(2003).Ultrastructural morphometry of capillary basement membrane thickness in normal and transgenic diabetic mice. *Anat Rec A Discov Mol Cell Evol Biol*, 271.332–341.
- Awad, A. S., Kalantarinia, K., & Siragy, H. M. (2003).Urinary and renal interstitial concentrations of TNF- $\alpha$  increase prior to the rise in albuminuria in diabetic rats. *Kidney Int*, 64, 1208–1213.
- Barkhof, F.,Heine, R.J., Kuijer, J.P., Kostense, P.J.,Rombouts, S.A., Scheltens, P.,*et al.* (2006). Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study.*Diabetes*, 55.334–340.
- Beckman, J.A., Creager, M.A., Libby, P. (2002). Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. *JAMA*, 287, 2570–2581.
- Bitzer.,B'ottinger.,Ju., Mundel., &Wu. (2005).TGF- $\beta$  concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis

- in podocytes. *Journal of the American Society of Nephrology*, 16 (11), 3211–3221.
- Boehmer, K., Brekken, R.A., Hausknecht, B., Hohenstein, B., Hugo, C.P.M., & Riess, R. (2006). Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. *Kidney International*. 69 (9), 1654–1661.
- Boulton, A.J. (1997). Foot problems in patients with diabetes mellitus. In: Pickup J, Williams G, ed. *Textbook of Diabetes*. London, United Kingdom: Blackwell Science, 1–58.
- Brenner, B.M., Cooper, M.E., Zeeuw, D., *et al.* (2001). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*, 345, 861–869.
- Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*, 54, 1615–25.
- Caramlau, I., Connock, M., Lloyd, C.E., Nefs, G., Nouwen, A., Peyrot, M., Pouver, F Winkley, K. (2011). Prevalence of depression in individuals with impaired glucose metabolism or undiagnosed diabetes: a systematic review and meta-analysis of the European Depression Diabetes (EDID) Research Consortium. *Diabetes Care*, 34, 752–762.
- Cukierman, T., Gerstein, H.C., Williamson, J.D. (2005). Cognitive decline and dementia in diabetes—systematic overview of prospective observational studies. *Diabetologia*, 48, 2460–2469.
- Chambless, L.E., Folsom, A.R., Rasmussen, M.L., *et al.* (1999). Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Diabetes Care*, 22, 1077–1083.
- Chambless, L.E., Ohira, T., Shahar, E., *et al.* (2006). Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities Study. *Stroke*, 37, 2493–2498.
- Cheng, H.T., Edwards, J.L., Vincent, A.M., *et al.* Diabetic neuropathy: mechanisms to management. *Pharmacol Ther*, 120.1–34.
- Chung, A.W., Luo, H., McManus, B.M., Okon, E.B., Padilla, E., Tejerina, T. (2005). Compromised arterial function in human type 2 diabetic patients. *Diabetes*, 54, 2415–2423.
- Draznin, B.B., Reusch, J.E. (2007). Atherosclerosis in diabetes and insulin resistance. *Diabetes Obes Metab*, 9, 455–463.

- Drummond, K., Mauer, M. (2002). The early natural history of nephropathy in type 1 diabetes, II: early renal structural changes in type 1 diabetes. *Diabetes*, *51*, 1580–1587.
- Emery, C.J., Griffiths, P.D., Harris, N.D., Selvarajah, D., Shaw, P.J., Tesfaye, S., *et al.* (2006). Early involvement of the spinal cord in diabetic peripheral neuropathy. *Diabetes Care*, *29*, 2664–2669.
- Eriksson, J. W., & Svensson, M. K. (2011) Change in the amount of body fat and IL-6 levels is related to altered insulin sensitivity in type 1 diabetes patients with or without diabetic nephropathy. *Horm. Metab. Res.* *43*, 209–215.
- Frank, R.N. (2004). Diabetic retinopathy. *N Engl J Med*, *350*, 48–58.
- Feaser, B., Kittner, S., Rohr, J., *et al.* (1996). Traditional risk factors and ischemic stroke in young adults: the Baltimore-Washington Cooperative Young Stroke Study. *Arch Neurol*, *53*, 603–607.
- Feldman, E.L., Hinder, L.M., O'Brien, P.D., Sakowski, S.A. (2014). ER stress in diabetic peripheral neuropathy: a new therapeutic target. *Antioxid Redox Signal*.
- Friedman, E.A. (1990). Diabetic Renal Disease. In Rifkin H, Porte D (eds): *Diabetes Mellitus: Theory and Practice*. Stamford, Conn: Appleton & Lange. 684-709.
- Garcia, J., Herrera, H., Muros, M., Mora, C., Navarro-Gonzalez, J. F., & Rivero, A. (2009). Pathogenic perspectives for the role of inflammation in diabetic nephropathy. *Clin. Sci*, *116*, 479–492.
- Glass, C.K., Witztum, J.L. (2001). Atherosclerosis: the road ahead. *Cell*, *104*, 503–516.
- Grant, L.M., Vinik, A.I., Witzke, K.A., *et al.* (2011). Loss of RAGE defense: a cause of Charcot neuroarthropathy? *Diabetes Care*, *34*, 1617–21.
- Griffin, J.W., Sheth, S., Sumner, C.J., *et al.* (2003). The spectrum of neuropathy in diabetes and impaired glucose tolerance. *Neurology*, *60*, 108–111.
- Groop, L., Henricsson, M., Janzon, L., Nilsson, A. (1997). The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. *Diabet Med*, *14*, 123–131.
- Harding, S. (2003). Concise clinical evidence: diabetic retinopathy. *BMJ*, *326*, 1023–1025.

- Hirai, F.E., Klein, B.E., Klein, R., Tielsch, J.M. (2011). Ten-year change in vision-related quality of life in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. *Ophthalmology*, 118, 353–358.
- Imaizumi, T., Yamagishi, S. (2005). Pericyte biology and diseases. *Int J Tissue React*, 27, 125–135.
- Ingale, K.G., Joshi, V.S., Thorve, V.S., Kshirsagar, A.D., Mohite, R.J., Vyawahare, N.S. (2011). Diabetes induced erectile dysfunction: epidemiology, pathophysiology and management. *J Diabetes Complications*, 25, 129–136.
- Keinanen-Kiukaanniemi, S., Koskela, P., Pajunpaa, H., Rajala, U. (2000). High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. *Diabetes Care*, 23, 957–961.
- King, G.L., Sheetz, M.J. (2002). Molecular understanding of hyperglycemia's adverse effects for diabetic complications. *JAMA*, 288, 2579–2588.
- Klein, R., Klein B.E.K., Moss S.E., *et al.* (1984). The Wisconsin Epidemiologic Study of Diabetic retinopathy: II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. *Arch Ophthalmol*, 102, 527–532.
- Kobayashi, K., Yamagishi, S., Yamamoto, H. (1993). Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. *Biochem Biophys Res Commun*, 190, 418–425.
- Kohner, E.M., Patel, V., Rassam, S.M. (1995). Role of blood flow and impaired autoregulation in the pathogenesis of diabetic retinopathy. *Diabetes*, 44, 603–607.
- Leichter, S.B., Mitchell, B.D., Vinik, A.I., *et al.* (1995). Epidemiology of the complications of diabetes. In Leslie RDG, Robbins DC (eds): *Diabetes: Clinical Science in Practice*. Cambridge: Cambridge University Press. 221.
- Liaudet, L., Pacher, P., Soriano, F.G., *et al.* (2002). The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. *Diabetes*, 51, 514–21.
- Norgaard, J.O., Rasch, R. (1983). Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. *Diabetologia*, 25, 280–287.

- Obrosova, I.G. (2009). Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. *Neurotherapeutics*, 6, 638–647.
- Ozcan, L., Seimon, T.A., Timmins, J.M., *et al.* (2009). Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. *J Clin Invest*, 119.2925–41.
- Ross, R. (1995). Cell biology of atherosclerosis. *Annu Rev Physiol*, 57,791–804.